Brief: Gamida Cell Announces FDA Acceptance Of Biologics License Application For Omidubicel With Priority Review
01/08/2022 13:02
Aug 1 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE
APPLICATION FOR OMIDUBICEL WITH PRIORITY REVIEW
* GAMIDA CELL LTD- PDUFA TARGET ACTION DATE IS JANUARY 30,
2023
Source text for Eikon: ID:nBw4H4Z1la
Further company coverage: GMDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq